{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:26:46Z","timestamp":1740162406670,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11096-020-00993-7","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T08:02:47Z","timestamp":1582185767000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-8603","authenticated-orcid":false,"given":"Marina","family":"Rovira-Illamola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Pag\u00e8s-Puigdemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Miquel","family":"Sotoca-Momblona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Mensa-Vendrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Barba-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Casasayas-Guilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"993_CR1","unstructured":"[Use of antihypertensive drugs in Spain during the period 2010\u20132017. Spanish Drug Agency]. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/informes-publicados\/informes-antihipertensivos-espana-2010-2017.htm. Accessed 24 Apr 2019."},{"key":"993_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","volume":"87","author":"A Rubio-Tapia","year":"2012","unstructured":"Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu T-T, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732\u20138.","journal-title":"Mayo Clin Proc"},{"key":"993_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.12780","volume":"40","author":"G Ianiro","year":"2014","unstructured":"Ianiro G, Bibb\u00f2 S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"993_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.5858\/arpa.2015-0204-RA","volume":"139","author":"E-YK Choi","year":"2015","unstructured":"Choi E-YK, McKenna BJ. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med. 2015;139:1242\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"993_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.12937","volume":"40","author":"L Marthey","year":"2014","unstructured":"Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40:1103\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"993_CR6","unstructured":"FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 2013. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm359477.htm. Accessed 17 May 2016."},{"key":"993_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.dld.2015.09.014","volume":"48","author":"M Esteve","year":"2016","unstructured":"Esteve M, Temi\u00f1o R, Carrasco A, Batista L, Del Val A, Bl\u00e9 M, et al. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48:154\u201361.","journal-title":"Dig Liver Dis"},{"key":"993_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3109\/00365521.2015.1074719","volume":"51","author":"A Schiepatti","year":"2016","unstructured":"Schiepatti A, Biagi F, Cumetti D, Luinetti O, Sonzogni A, Mugellini A, et al. Olmesartan-associated enteropathy: new insights on the natural history? Report of two cases. Scand J Gastroenterol. 2016;51:152\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"993_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.aprim.2016.09.008","volume":"49","author":"M Curieses","year":"2017","unstructured":"Curieses M, Barreiro E, Izquierdo M, Ram\u00f3n FJ. [Spruelike enteropathy associated with olmesartan]. Aten Primaria. 2017;49:369\u201370.","journal-title":"Aten Primaria"},{"key":"993_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.gastrohep.2014.05.006","volume":"38","author":"S Agudo","year":"2015","unstructured":"Agudo S. [Sprue-like enteropathy due to olmesartan: a case report]. Gastroenterol Hepatol. 2015;38:108\u20139.","journal-title":"Gastroenterol Hepatol"},{"key":"993_CR11","first-page":"647","volume":"107","author":"C Mu\u00f1oz-Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz-Mu\u00f1oz C, L\u00f3pez-Vivancos J, Huaman W, Garc\u00eda-Cors M. Sprue-like enteropathy due to olmesartan. Rev Esp Enferm Dig. 2015;107:647\u20138.","journal-title":"Rev Esp Enferm Dig"},{"key":"993_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s00508-015-0882-8","volume":"127","author":"E Fabian","year":"2015","unstructured":"Fabian E, Schiller D, Wenzl H, Lackner C, Donnerer J, Ziachehabi A, et al. Clinical-pathological conference series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20\u00a0kg. Wien Klin Wochenschr. 2015;127:974\u201380.","journal-title":"Wien Klin Wochenschr"},{"key":"993_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.medcli.2014.06.006","volume":"144","author":"L T\u00e9llez","year":"2015","unstructured":"T\u00e9llez L, Crespo L, Cano A, Moreira V. [Enteropathy by olmesartan]. Med Clin. 2015;144:140\u20131.","journal-title":"Med Clin"},{"key":"993_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.medcli.2014.03.031","volume":"144","author":"A T\u00e9llez","year":"2015","unstructured":"T\u00e9llez A, Pellic\u00e9 M, Llobell A, Milisenda JC. [Enteropathy associated with chronic use of olmesartan]. Med Clin. 2015;144:139\u201340.","journal-title":"Med Clin"},{"key":"993_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/00365521.2015.1083051","volume":"51","author":"N Imperatore","year":"2016","unstructured":"Imperatore N, Tortora R, Capone P, Caporaso N, Rispo A. An emerging issue in differential diagnosis of diarrhea: sprue-like enteropathy associated with olmesartan. Scand J Gastroenterol. 2016;51:378\u201380.","journal-title":"Scand J Gastroenterol"},{"key":"993_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/1060028016665862","volume":"50","author":"G Famularo","year":"2016","unstructured":"Famularo G, Minisola G. Relapsing olmesartan-associated ileitis. Ann Pharmacother. 2016;50:1070.","journal-title":"Ann Pharmacother"},{"key":"993_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ccr3.531","volume":"4","author":"N Hammoudi","year":"2016","unstructured":"Hammoudi N, Dior M, Giraud V, Coffin B. Olmesartan-induced enteropathy associated with cutaneous lesions. Clin Case Reports. 2016;4:379\u201382.","journal-title":"Clin Case Reports"},{"key":"993_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.nefro.2016.10.005","volume":"37","author":"L Roca-Argente","year":"2017","unstructured":"Roca-Argente L, Diaz-Jaime F-C, L\u00f3pez-Romero L-C, Manzur-Aguilar Y, Moll-Guillem J-L, del Val-Anto\u00f1ana A, et al. Acute kidney injury secondary to diarrhea caused by \u201csprue-like\u201d enteropathy associated with olmesartan. Nefrologia. 2017;37:548\u201350.","journal-title":"Nefrologia"},{"key":"993_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s11739-018-1963-2","volume":"14","author":"M Bonzi","year":"2019","unstructured":"Bonzi M, Fiorelli EM, Montanelli G, Furlan L, Solbiati M. A simple treatment for a potentially life-threatening cause of malabsorption. Intern Emerg Med. 2019;14:967\u201371.","journal-title":"Intern Emerg Med"},{"key":"993_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.17235\/reed.2016.4340\/2016","volume":"108","author":"E S\u00e1ez-Gonz\u00e1lez","year":"2016","unstructured":"S\u00e1ez-Gonz\u00e1lez E, D\u00edaz-Jaime FC, del Val-Anto\u00f1ana A. Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use. Rev Esp Enferm Dig. 2016;108:685\u20136.","journal-title":"Rev Esp Enferm Dig"},{"key":"993_CR21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/ajg.2015.291","volume":"110","author":"A Marco-Marqu\u00e9s","year":"2015","unstructured":"Marco-Marqu\u00e9s A, Sanahuja-Martinez A, Bosca-Watts MM, Tosca-Cuquerella J, Mas-Mercader P, Andrade-Gamarra V, et al. Could HLA-DQ suggest why some patients have olmesartan-related diarrhea and others don\u2019t? Am J Gastroenterol. 2015;110:1507\u20138.","journal-title":"Am J Gastroenterol"},{"key":"993_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0125024","volume":"10","author":"S Scialom","year":"2015","unstructured":"Scialom S, Malamut G, Meresse B, Guegan N, Brousse N, Verkarre V, et al. Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy. PLoS ONE. 2015;10:1\u20139.","journal-title":"PLoS ONE"},{"key":"993_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.regg.2016.09.002","volume":"52","author":"E Calvo","year":"2016","unstructured":"Calvo E, Martinez C, Gonzalez MP, Omiste T. [Sprue-like enteropathy in the elderly treated with olmesartan]. Rev Esp Geriatr Gerontol. 2016;52:223\u20134.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"993_CR24","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/apt.13000","volume":"40","author":"A Rubio-Tapia","year":"2014","unstructured":"Rubio-Tapia A. Editorial: sprue-like enteropathy associated with olmesartan\u2014broadening the differential diagnosis of enteropathy. Aliment Pharmacol Ther. 2014;40:1362\u20133.","journal-title":"Aliment Pharmacol Ther"},{"key":"993_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.gastrohep.2014.11.007","volume":"38","author":"JL Ulla-Rocha","year":"2015","unstructured":"Ulla-Rocha JL, Lopez-Pi\u00f1eiro S, Puga-Gimenez M. [Acute renal failure secondary to diarrhea due to sprue-like enteropathy associated with olmesartan]. Gastroenterol Hepatol. 2015;38:514\u20135.","journal-title":"Gastroenterol Hepatol"},{"key":"993_CR26","first-page":"292","volume":"108","author":"A Campos-Ruiz","year":"2016","unstructured":"Campos-Ruiz A, Urtasun-Arlegui L, Marra-L\u00f3pez-Valenciano C. Sprue-like enteropathy linked to olmesartan. Rev Esp Enferm Dig. 2016;108:292\u20133.","journal-title":"Rev Esp Enferm Dig"},{"key":"993_CR27","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/gutjnl-2015-309690","volume":"65","author":"M Basson","year":"2016","unstructured":"Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016;65:1664\u20139.","journal-title":"Gut"},{"key":"993_CR28","unstructured":"Report Suspected Reaction (Sprue-like enteropathy)\u2014number of individual cases identified in Eudravigilance for OLMESARTAN (up to Feb 2019). http:\/\/www.adrreports.eu\/es\/disclaimer.html. Accessed 11 Mar 2019."},{"key":"993_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/MCG.0000000000000383","volume":"49","author":"A Negro","year":"2015","unstructured":"Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol. 2015;49:794.","journal-title":"J Clin Gastroenterol"},{"key":"993_CR30","unstructured":"[To better treat, drugs to be discarded: 2015 review]. Rev Prescrire 2015;35:144\u201351."},{"key":"993_CR31","unstructured":"[To better treat, drugs to be discarded: 2019 review]. Rev Prescrire. 2019;39:131\u201341."},{"key":"993_CR32","unstructured":"[High blood pressure drugs based on olmesartan: why are they no longer reimbursed? What should we do?]. https:\/\/www.has-sante.fr\/\/portail\/jcms\/c_2620725\/fr\/medicaments-de-l-hypertension-arterielle-a-base-d-olmesartan-pourquoi-ne-sont-ils-plus-rembourses-quelle-conduite-a-tenir. Accessed 18 July 2016."},{"key":"993_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","volume":"50","author":"N Burbure","year":"2016","unstructured":"Burbure N, Lebwohl B, Arguelles-Grande C, Green PHR, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127\u201334.","journal-title":"Hum Pathol"},{"key":"993_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"993_CR35","unstructured":"Gallardo R, Mart\u00edn A, Escudero R, Lovera M. [Improved antihypertensives prescription avoiding risks with olmesartan]. In: XXII Congress of the Spanish Society of Primary Care Pharmacists; 2017."},{"key":"993_CR36","unstructured":"Tirado M, Tejada F, Lloret A. [Adverse drug reactions and active communication. In behalf of olmesartan]. In: XXII Congress of the Spanish Society of Primary Care Pharmacists; 2017."},{"key":"993_CR37","unstructured":"Rodr\u00edguez J, Martinanco J, Ruso E. [Intervention on olmesartan\u2019s prescription]. In: XXII Congress of the Spanish Society of Primary Care Pharmacists; 2017."},{"key":"993_CR38","unstructured":"Molina R, Alberte C, Salado I, Rilo J, Flores M, Dom\u00ednguez M. [Impact of a safety alert when prescribing olmesartan in a primary care area]. In: XXII Congress of the Spanish Society of Primary Care Pharmacists; 2017."},{"key":"993_CR39","unstructured":"[Argument of the Pharmaceutical prescription\u2019s quality index, 2018 version. Medication Area. CatSalut]. 2018. https:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/farmacia-medicaments\/proveidors-del-medicament\/objectius-vinculats-part-variable-contractes\/atencio-primaria\/. Accessed 15 May 2018."},{"key":"993_CR40","unstructured":"[Pharmaceutical prescription\u2019s quality index, 2018 version]. Medication area. CatSalut. https:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/farmacia-medicaments\/proveidors-del-medicament\/objectius-vinculats-part-variable-contractes\/atencio-primaria\/. Accessed 15 May 2018."},{"key":"993_CR41","unstructured":"In brief: Olmesartan and sprue-like enteropathy. Med Lett Drugs Ther 2018;60:24."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-00993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-020-00993-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-00993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T19:13:41Z","timestamp":1613762021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-020-00993-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-00993-7","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}